Molecular diagnostics specialist Variantyx, situated in Framingham, Massachusetts, has secured $36 million in investment.
Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures were among the backers. With this round, nearly $125 million has been invested in Variantyx overall.
The firm plans to take advantage of the potential to offer genome-based treatment to a greater number of patients by using the money for further technological and commercial expansion.
Variantyx, a technology-driven molecular diagnostics firm led by CEO Haim Neerman, offers solutions for the markets of precision oncology, genetic diseases, and reproductive health. Clinicians may better prescribe individualized treatments and increase diagnostic skills by understanding an individual’s genetic composition thanks to Variantyx’s patented whole genome analysis tools.
“The fundraising shows that investors continue to have faith in our capacity to meet the company’s long-term objectives.Due to our unparalleled diagnostic abilities and enhanced personalized treatment recommendations, we have the potential to significantly improve patient outcomes for a growing segment of the population as we continue to broaden our commercial footprint, all the while increasing value for shareholders.”
CEO Haim Neerman
Its Investors:-
- Peregrine Ventures
- Pitango HealthTech
- New Era Capital Partners
- Bosch Ventures
Concerning Varianytx
Variantyx is a technology-driven, award-winning precision medicine firm offering game-changing solutions for the markets in precision cancer, genetic diseases, and reproductive health. With the use of Variantyx’s patented whole genome analysis tools, medical professionals and patients may get a deeper understanding of an individual’s genetic composition, enabling more precise diagnosis and more individualized therapy recommendations.
